Merck Group Explores Additive Manufacturing for Pharmaceuticals and Bioprinting
Merck Group is investigating the integration of additive manufacturing across various sectors, including the development of digital pills and advancements in 3D bioprinting.
Merck Group is actively exploring the potential of additive manufacturing (AM) technologies to revolutionize its product development and manufacturing processes. This includes a focus on creating "digital pills," which are designed to incorporate electronic components for enhanced drug delivery and patient monitoring.
The company's research extends into the field of 3D bioprinting, aiming to leverage this advanced technique for applications in drug discovery and development. By precisely depositing biological materials, Merck seeks to create complex tissue models or even functional biological constructs.
These explorations into AM and bioprinting are part of Merck's broader strategy to embrace cutting-edge technologies that can lead to more personalized medicine, improved therapeutic outcomes, and novel approaches to pharmaceutical research. The integration of digital technologies with bioprinting holds promise for accelerating the development cycle and offering new solutions for unmet medical needs.
Merck's exploration of additive manufacturing for digital pills and bioprinting signifies a significant push towards personalized medicine and advanced drug development. This integration of digital and biological fabrication aligns with the broader additive manufacturing trend of creating complex, customized structures. Such advancements could accelerate R&D, enable novel drug delivery systems, and potentially lead to in-situ production of biological materials for research and therapeutic purposes.
Edited by the news editor with AI from the original report — please refer to the original source.